Shots:
- The EC has granted ODD to ABO-101 for the treatment of primary hyperoxaluria
- ABO-101 is being evaluated in an open-label global P-I/II (redePHine) study assessing safety, tolerability, PK/PD, & preliminary efficacy of a single dose of ABO-101 in pts with PH type 1
- ABO-101 is a one-time, liver-directed gene-editing therapy that uses an Acuitas-licensed LNP to deliver Type V CRISPR Cas12i2 mRNA & a guide RNA targeting the HAO1 gene, aiming to permanently reduce PH1-associated oxalate production
Ref: Globenewswire | Image: Chiesi & Arbor | Press Release
Related News: Chiesi Reports the EC Approval of Lojuxta to Treat Homozygous Familial Hypercholesterolaemia in Pediatric Patients
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
